Clinical trial to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM95573 in solid tumor
Not Applicable
Active, not recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0001539
- Lead Sponsor
- Hanmi Pharm
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
1. Patients must be 19 years of age or older
2. Subjects who have provided voluntary consent to participate in the study, and signed the written consent document.
3. Estimated life expectancy of at least 12 weeks
4. Histologically or cytologically confirmed advanced solid tumor
Exclusion Criteria
1.Symptomatic or uncontrolled central nervous system metastases
2. Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug.
3. Patients who, in the investigator’s opinion, are not suitable for the study for any other reason.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose limiting toxicity
- Secondary Outcome Measures
Name Time Method Efficaty and Pharmacokinetics